TELA Bio, Inc. Files 8-K on Financials and Operations

Ticker: TELA · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1561921

Tela Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyTela Bio, Inc. (TELA)
Form Type8-K
Filed DateMar 21, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, sec-filing

TL;DR

TELA Bio dropped an 8-K detailing financials & operations. Check it for the latest.

AI Summary

On March 21, 2024, TELA Bio, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing also includes disclosures related to Regulation FD and other events, along with financial statements and exhibits. The company is headquartered in Malvern, Pennsylvania.

Why It Matters

This filing provides investors with crucial updates on TELA Bio's financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing providing standard financial and operational updates, not indicating immediate significant risk.

Key Players & Entities

  • TELA Bio, Inc. (company) — Registrant
  • Malvern, Pennsylvania (location) — Principal executive offices
  • March 21, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing for TELA Bio, Inc.?

The primary purpose is to report on TELA Bio, Inc.'s Results of Operations and Financial Condition, as well as Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on March 21, 2024.

Where are TELA Bio, Inc.'s principal executive offices located?

TELA Bio, Inc.'s principal executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.

What is TELA Bio, Inc.'s telephone number?

TELA Bio, Inc.'s telephone number, including area code, is (484) 320-2930.

What is TELA Bio, Inc.'s Standard Industrial Classification code?

TELA Bio, Inc.'s Standard Industrial Classification code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

Filing Stats: 716 words · 3 min read · ~2 pages · Grade level 9.2 · Accepted 2024-03-21 16:15:57

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On March 21, 2024, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01

Item 7.01 Regulation FD Disclosure. On March 21, 2024, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01

Item 8.01 Other Events. On March 21, 2024, the Company issued a press release announcing the U.S. commercial launch of LIQUIFIX FIX8 Laparoscopic and LIQUIFIX Precision Open Hernia Mesh Fixation Devices. A copy of this press release is filed as Exhibit 99.3 hereto and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated March 21, 2024. 99.2 Corporate Slide Deck, dated March 21, 2024. 99.3 Press Release of TELA Bio, Inc., dated March 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: March 21, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.